JP Morgan Upgrades Editas Medicine to Neutral, Announces $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Brian Cheng has upgraded Editas Medicine (NASDAQ:EDIT) from Underweight to Neutral and announced a price target of $8.

October 18, 2023 | 9:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Editas Medicine has been upgraded to Neutral from Underweight by JP Morgan, with a new price target of $8.
The upgrade from JP Morgan is a positive signal for Editas Medicine. It indicates that the analyst sees potential in the company's stock, which could lead to increased investor interest and potentially a rise in the stock price. The new price target of $8 also suggests that the analyst believes the stock is undervalued at its current price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100